Clinical characteristics and prognostic implications in patients with HER2-low breast cancer undergoing neoadjuvant chemotherapy: a retrospective cohort study

被引：0
|
作者：
Zheng, Ang [1 ]
He, Junlin [2 ]
Li, Muyao [1 ]
Yao, Fan [1 ]
Jin, Feng [1 ]
Chen, Bo [1 ]
Wang, Xin [2 ]
机构：
[1] China Med Univ, Hosp 1, Shenyang, Peoples R China
[2] China Med Univ, Shenyang, Peoples R China
来源：
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2025年 / 55卷
关键词：
HER2; Low; Breast Cancer;
D O I：
10.1016/j.lanwpc.2024.101378
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
    Shang, Jiuyan
    Sun, Xuemei
    Xu, Zihang
    Cai, Lijing
    Liu, Chang
    Wu, Si
    Liu, Yueping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [22] HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category
    Karakas, Cansu
    Tyburski, Haley
    Weiss, Anna
    Akkipeddi, Sajal Medha K.
    Dhakal, Ajay
    Skinner, Kristin
    Zhang, Huina
    HUMAN PATHOLOGY, 2023, 142 : 34 - 41
  • [23] Genomic and transcriptomic landscape of HER2-low breast cancer
    Bansal, Rani
    Adeyelu, Tolulope
    Elliott, Andrew
    Walker, Phillip
    Bustos, Matias A.
    Rodriguez, Estelamari
    Accordino, Melissa K.
    Meisel, Jane
    Gatti-Mays, Margaret E.
    Hsu, Emily
    Lathrop, Kate
    Kaklamani, Virginia
    Oberley, Matthew
    Sledge, George
    Sammons, Sarah L.
    Graff, Stephanie L.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, 209 (02) : 323 - 330
  • [24] Pathological complete response rate and clinical outcome after neoadjuvant therapy of HER2-low breast cancer: A National Cancer Database Analysis
    Zhong, Guansheng
    Song, Dajiang
    Lou, Weiyang
    Wei, Bajin
    Chen, Yaomin
    Cui, Haidong
    Hu, Jingjing
    Dong, Huaying
    Chen, Jie
    Dai, Zhijun
    EJSO, 2023, 49 (11):
  • [25] HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
    Agostinetto, Elisa
    Rediti, Mattia
    Fimereli, Danai
    Debien, Veronique
    Piccart, Martine
    Aftimos, Philippe
    Sotiriou, Christos
    de Azambuja, Evandro
    CANCERS, 2021, 13 (11)
  • [26] Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer
    Zhao, Yingying
    Chen, Xinru
    Wang, Yaohui
    Zhang, Xueqing
    Ye, Yumei
    Xu, Shuguang
    Zhou, Liheng
    Lin, Yanping
    Lu, Jingsong
    Yin, Wenjin
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [27] Investigating HER2-Low in Early Breast Cancer: Prognostic Implications and Age-Related Prognostic Stratification
    Chen, Endong
    Chen, Chen
    Chen, Yingying
    You, Jie
    Chen, Nan
    Xu, Shenlin
    Wang, Qingxuan
    Cai, Yefeng
    Hu, Xiaoqu
    Li, Quan
    CANCER MEDICINE, 2025, 14 (04):
  • [28] Improving HER2 testing reproducibility in HER2-low breast cancer
    Sajjadi, Elham
    Venetis, Konstantinos
    Ivanova, Mariia
    Fusco, Nicola
    CANCER DRUG RESISTANCE, 2022, 5 (04) : 882 - 888
  • [29] Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer
    Lacruz, Maria Elena
    Thies, Saskia
    Schmidt-Pokrzywniak, Andrea
    Wittenberg, Ian
    Engler, Tobias
    Reinwald, Fabian
    Klinkhammer-Schalke, Monika
    Zeissig, Sylke Ruth
    Franke, Bianca
    Weitmann, Kerstin
    Ignatov, Atanas
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [30] Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
    Guan, Feng
    Ju, Xianli
    Chen, Lixia
    Ren, Jiacai
    Ke, Xiaokang
    Luo, Bin
    Huang, Aoling
    Yuan, Jingping
    DIAGNOSTIC PATHOLOGY, 2024, 19 (01)
12345